Fabry Disease
Fabry disease is a rare, inherited metabolic disorder that affects the body's ability to break down and dispose of a fatty substance called globotriaosylceramide. This can result in the accumulation of fatty substances in various organs, including the kidneys, heart, and brain. The disease is caused by a deficiency in the enzyme alpha-galactosidase A, which is responsible for breaking down globotriaosylceramide. This deficiency leads to the accumulation of the substance in various organs, leading to a range of symptoms, including pain in the hands and feet, skin rashes, and gastrointestinal issues. Neurological symptoms of Fabry disease can include stroke, transient ischemic attacks, and seizures. These symptoms are caused by the accumulation of fatty substances in the blood vessels that supply oxygen to the brain. Therapies for Fabry disease include enzyme replacement therapy, which involves intravenous infusions of the missing enzyme. This therapy can help reduce the buildup of fatty substances in the body and improve symptoms. Other treatments may include pain management, anti-seizure medications, and cardiovascular medications. Additionally, genetic counseling and testing may be recommended for family members of individuals with Fabry disease to identify those who may be carriers of the disease. In summary, Fabry disease is a rare metabolic disorder with neurological symptoms that can benefit from enzyme replacement therapy and other treatments aimed at managing symptoms and preventing complications.
← Journal of Neurological Research And Therapy